Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients

BACKGROUND: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8(+), but not CD4(+), T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Snook, Adam E., Baybutt, Trevor R., Xiang, Bo, Abraham, Tara S., Flickinger, John C., Hyslop, Terry, Zhan, Tingting, Kraft, Walter K., Sato, Takami, Waldman, Scott A.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477737/
https://ncbi.nlm.nih.gov/pubmed/31010434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0576-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars